StockMarketWire.com - Serious disease focused PureTech Health said the first participant had been dosed in a clinical study of a treatment for lymphoedema and other fibrotic conditions.

PureTech Health said there was currently not FDA-approved drugs to treat lymphoedema, a painful and chronic condition affecting around 1mindividuals in the US alone, including breast cancer survivors.

The Phase 1 study for the treatment, dubbed LYT-100, would evaluate its safety, tolerability and pharmacokinetic profile in healthy participants.

It was a follow-up to a single ascending dose clinical trial of LYT-100 in healthy individuals that was conducted by Auspex.

Results were expected this year and would enable the initiation of a proof-of-concept study in people with breast cancer-related, upper limb secondary lymphoedema later in 2020.




Story provided by StockMarketWire.com